MX2020004855A - Metodos utiles en la sintesis de analogos de halicondrina b. - Google Patents

Metodos utiles en la sintesis de analogos de halicondrina b.

Info

Publication number
MX2020004855A
MX2020004855A MX2020004855A MX2020004855A MX2020004855A MX 2020004855 A MX2020004855 A MX 2020004855A MX 2020004855 A MX2020004855 A MX 2020004855A MX 2020004855 A MX2020004855 A MX 2020004855A MX 2020004855 A MX2020004855 A MX 2020004855A
Authority
MX
Mexico
Prior art keywords
halichondrin
analogs
synthesis
methods useful
eribulin
Prior art date
Application number
MX2020004855A
Other languages
English (en)
Other versions
MX384292B (es
Inventor
Yongbo Hu
Huiming Zhang
Hiroyuki Chiba
Yuki Komatsu
Bryan M Lewis
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2020004855A publication Critical patent/MX2020004855A/es
Publication of MX384292B publication Critical patent/MX384292B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En general, la presente invención se refiere a métodos mejorados útiles en la síntesis de análogos de halicondrina B, tales como eribulina, y a sales farmacéuticamente aceptables de los mismos (por ejemplo, mesilato de eribulina).
MX2020004855A 2013-12-06 2014-12-05 Metodos utiles en la sintesis de analogos de halicondrina b. MX384292B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912714P 2013-12-06 2013-12-06
PCT/US2014/068834 WO2015085193A1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Publications (2)

Publication Number Publication Date
MX2020004855A true MX2020004855A (es) 2021-07-08
MX384292B MX384292B (es) 2025-03-14

Family

ID=53270478

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020004855A MX384292B (es) 2013-12-06 2014-12-05 Metodos utiles en la sintesis de analogos de halicondrina b.
MX2019011926A MX376869B (es) 2013-12-06 2014-12-05 Metodos utiles en la sintesis de analogos de halicondrina b.
MX2016006891A MX370611B (es) 2013-12-06 2014-12-05 Metodos utiles en la sintesis de analogos de halicondrina b.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2019011926A MX376869B (es) 2013-12-06 2014-12-05 Metodos utiles en la sintesis de analogos de halicondrina b.
MX2016006891A MX370611B (es) 2013-12-06 2014-12-05 Metodos utiles en la sintesis de analogos de halicondrina b.

Country Status (13)

Country Link
US (4) US9303039B2 (es)
EP (2) EP3077399B1 (es)
JP (3) JP6443812B2 (es)
CN (1) CN105916861B (es)
BR (1) BR112016012237B1 (es)
CA (1) CA2931788C (es)
ES (1) ES2723355T3 (es)
HU (1) HUE043088T2 (es)
IL (4) IL245661A0 (es)
MX (3) MX384292B (es)
RU (1) RU2676486C1 (es)
SG (2) SG10201805024YA (es)
WO (1) WO2015085193A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046436T2 (hu) * 2004-06-03 2020-02-28 Eisai R&D Man Co Ltd Köztitermékek halikondrin B elõállításához
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG10201805024YA (en) * 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
RU2020141025A (ru) 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
KR102404629B1 (ko) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
JP7168580B2 (ja) 2017-04-05 2022-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびその使用
WO2018217894A1 (en) * 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
WO2019099646A1 (en) 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11542269B2 (en) 2018-01-03 2023-01-03 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2020016847A2 (en) * 2018-07-20 2020-01-23 Dr. Reddy’S Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
US20210340156A1 (en) * 2018-10-09 2021-11-04 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020110146A1 (en) * 2018-11-28 2020-06-04 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2022101931A1 (en) * 2020-11-10 2022-05-19 Natco Pharma Limited Process for the preparation of eribulin and its intermediates
CN113354659B (zh) * 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
CN114380840B (zh) * 2022-01-27 2024-01-26 江苏慧聚药业股份有限公司 艾日布林的合成
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (es) 1992-09-09 1995-09-01 Hoechst Ag
US6194586B1 (en) * 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
DK1087960T3 (da) 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
HUE046436T2 (hu) * 2004-06-03 2020-02-28 Eisai R&D Man Co Ltd Köztitermékek halikondrin B elõállításához
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンbアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
WO2009014105A1 (ja) 2007-07-20 2009-01-29 Yamada Apiculture Center, Inc. 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
WO2009064029A1 (en) 2007-11-16 2009-05-22 Eisai R & D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG10201805024YA (en) * 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
RU2020141025A (ru) 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
KR102404629B1 (ko) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체

Also Published As

Publication number Publication date
ES2723355T3 (es) 2019-08-26
IL265640A (en) 2019-05-30
SG11201604545XA (en) 2016-07-28
US20160176895A1 (en) 2016-06-23
BR112016012237A2 (es) 2017-08-08
JP2020059739A (ja) 2020-04-16
IL273736B (en) 2021-03-25
CA2931788A1 (en) 2015-06-11
EP3505520A1 (en) 2019-07-03
IL265640B (en) 2020-04-30
EP3077399A4 (en) 2017-05-10
MX2019011926A (es) 2019-11-18
CN105916861A (zh) 2016-08-31
IL281275A (en) 2021-04-29
WO2015085193A1 (en) 2015-06-11
US20170298078A1 (en) 2017-10-19
JP6905041B2 (ja) 2021-07-21
IL281275B (en) 2021-12-01
IL245661A0 (en) 2016-06-30
EP3077399A1 (en) 2016-10-12
CN105916861B (zh) 2018-12-14
US10450324B2 (en) 2019-10-22
MX376869B (es) 2025-03-07
MX2016006891A (es) 2017-06-12
US9303039B2 (en) 2016-04-05
IL273736A (en) 2020-05-31
SG10201805024YA (en) 2018-07-30
MX370611B (es) 2019-12-18
JP6634135B2 (ja) 2020-01-22
MX384292B (es) 2025-03-14
JP2019031530A (ja) 2019-02-28
BR112016012237B1 (pt) 2023-02-07
JP2016540752A (ja) 2016-12-28
CA2931788C (en) 2022-05-24
US9695188B2 (en) 2017-07-04
US20190010166A1 (en) 2019-01-10
US20150158881A1 (en) 2015-06-11
EP3077399B1 (en) 2019-02-20
HUE043088T2 (hu) 2019-08-28
US10030032B2 (en) 2018-07-24
JP6443812B2 (ja) 2018-12-26
RU2676486C1 (ru) 2018-12-29

Similar Documents

Publication Publication Date Title
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CR20150370A (es) Compuestos antivirales
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
CR20140464A (es) Compuestos de heterociclilo
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY35469A (es) Moduladores de p2x7
MX2014014166A (es) Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica.
BR112016014180A2 (pt) reguladores de nrf2
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
UY34697A (es) Métodos para preparar análogos de nucleótidos
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
SV2016005294A (es) 2-amino-6-metil-4,4a,5,6-tetrahidropirano(3,4-d)(1,3)tiazin-8a(8h)-il-1,3-tiazol-4-ilamidas
DOP2013000307A (es) Antagonistas de trpv4
CR20150440A (es) Nuevos derivados de piridina
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
CR20150511A (es) Nuevos derivados de purina
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
CY1119871T1 (el) Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων
MX2015014470A (es) Analogos de combretastatina.